Background: ... We assessed clinical utility of ctDNA NGS for ALK testing for non-Sq-NSCLC in Asia... Conclusions: NGS testing for ALK fusions and genomic alterations in plasma ctDNA has clinical utility in non-Sq-NSCLC patients in guiding ALK targeted treatment at initial diagnosis and upon cancer progression. Detection rate and distribution of ALK fusion partners are comparable to existing data of tumor ALK testing. Further data on ALK treatment outcomes of patients with detectable ALK fusion on plasma ctDNA is warranted. READ ARTICLE
Annals of Oncology DOI:10.1016/j.annonc.2020.10.300
Authors: K. W. C. Lee, S. T. Wu, P. Y. Lo, C. T. Choy, T. C. Kwong, Y. T. N. Lau, L. Lin, S. W. Lau